07.01.20|Golan Hazani The Israel-based cancer treatment developer wants to raise $100 million according to a $400 million company valuation
29.05.19|Adi PickThe Israel-based company intends to use the new round of funding to advance the clinical development of its anti-cancer product
24.12.18|Lilach BaumerThe investment is part of a licensing option agreement signed between the two companies